Article content
TORONTO, Jan. 03, 2025 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (“The Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announces that it has granted an aggregate of 800,000 stock options to two of the Company’s three directors at an exercise price of $0.22 per share. The stock options vest immediately on the grant date and have a term of five years, expiring on January 2, 2030. The Chairman and CEO, Fabio Chianelli, did not receive any stock options.
Article content
About PharmaTher Holdings Ltd.
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the development and commercialization of KETARX™ (Ketamine) to fulfill unmet global medical needs for anesthesia, sedation, pain, mental health, mood, and contraindication medical indications. . Read more at PharmaTher.com.
For more information about PharmaTher, please contact:
Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Phone: 1-888-846-3171
Email: [email protected]
Official website: www.pharmather.com
Neither the Canadian Securities Exchange nor its Legal Services Provider has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Warning Statement
This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “near”, “can”, “certain”, “may”, “intend”, “expect”, “believe”, “will”, “expect”, “estimate”, “likely”, ” intent”, “may”, “plan”, “proposed”, “lead”, “look”, “expect”, and similar expressions and statements regarding matters that are not historical facts are intended to identify forward-looking information and are based on PharmaTher Holdings Ltd. (the “Company”) current belief or assumption regarding the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions made by the Company on the date of the information and is subject to known and unknown risks, uncertainties, and other factors that could cause actual results or events to differ materially from those anticipated by the forward-looking information. Given these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The above statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in the Company’s management’s discussion and analysis for the three months ended August 31, 2024 through October 24, 2024, namely. available in the Company profile at www.sedarplus.ca.
This news release does not constitute an offer to sell or solicitation of an offer to buy, and will not constitute an offer, solicitation or sale in any state, province, territory or territory where such offer, solicitation or sale would previously have been unlawful. in registering or qualifying under the securities laws of any state, province, territory or territory.
Share this article on your social network
Source link
